Mechanisms mediating environmental chemical-induced endocrine disruption in the adrenal gland

Frontiers in Endocrinology

Volumn 6, Issue MAR, 2015, Pages

  Martinez Arguelles, Daniel B ^a   Papadopoulos, Vassilios ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Adrenal gland; DEHP; Endocrine disruptors; Epigenetics; Inflammation; Peroxisome proliferator activated receptor; Phthalates; Reduced representation bisulfite sequencing

Indexed keywords

CHOLESTEROL; CORTICOTROPIN; CORTICOTROPIN RECEPTOR; ENDOCRINE DISRUPTOR; ENVIRONMENTAL CHEMICAL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHTHALIC ACID 2 ETHYLHEXYL MONOESTER;

ADRENAL GLAND; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; CELL MIGRATION; CHOLESTEROL METABOLISM; ENVIRONMENTAL EXPOSURE; EPIGENETICS; FETUS DEVELOPMENT; HUMAN; LEYDIG CELL; NONHUMAN; ORGANOGENESIS; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; STEROIDOGENESIS;

EID: 84926635150     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00029     Document Type: Review

References (121)

1. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, et al. Endocrine-disrupting chemicals: an endocrine society scientific statement. Endocr Rev (2009) 30:293-342. doi: 10.1210/er.2009-0002
2. Colborn T. Neurodevelopment and endocrine disruption. Environ Health Perspect (2004) 112:944-9. doi:10.1289/ehp.6601
3. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science (2010) 327:1345-50. doi:10.1126/science.1177319
4. Vandenberg LN. Low-dose effects of hormones and endocrine disruptors. Vitam Horm (2014) 94:129-65. doi:10.1016/B978-0-12-800095-3.00005-5
5. Wild CP. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev (2005) 14:1847-50. doi:10.1158/1055-9965.EPI-05-0456
6. Vrijheid M, Slama R, Robinson O, Chatzi L, Coen M, van den Hazel P, et al. The human early-life exposome (HELIX): project rationale and design. Environ Health Perspect (2014) 122:535-44. doi:10.1289/ehp.1307204
7. Vuorinen A, Odermatt A, Schuster D. In silico methods in the discovery of endocrine disrupting chemicals. J Steroid Biochem Mol Biol (2013) 137:18-26. doi:10.1016/j.jsbmb.2013.04.009
8. Hinson JP, Raven PW. Effects of endocrine-disrupting chemicals on adrenal function. Best Pract Res Clin Endocrinol Metab (2006) 20:111-20. doi:10.1016/j.beem.2005.09.006
9. Sanderson JT. The steroid hormone biosynthesis pathway as a target for endocrine-disrupting chemicals. Toxicol Sci (2006) 94:3-21. doi:10.1093/toxsci/kfl051
10. Barker DJ. The fetal and infant origins of adult disease. BMJ (1990) 301:1111. doi:10.1136/bmj.301.6761.1111
11. Hatano O, Takakusu A, Nomura M, Morohashi K. Identical origin of adrenal cortex and gonad revealed by expression profiles of Ad4BP/SF-1. Genes Cells (1996) 1:663-71. doi:10.1046/j.1365-2443.1996.00254.x
12. Keegan CE, Hammer GD. Recent insights into organogenesis of the adrenal cortex. Trends Endocrinol Metab (2002) 13:200-8. doi:10.1016/S1043-2760(02)00602-1
13. Hammer GD, Parker KL, Schimmer BP. Minireview: transcriptional regulation of adrenocortical development. Endocrinology (2005) 146:1018-24. doi:10.1210/en.2004-1385
14. Griswold SL, Behringer RR. Fetal Leydig cell origin and development. Sex Dev (2009) 3:1-15. doi:10.1159/000200077
15. Mesiano S, Jaffe RB. Developmental and functional biology of the primate fetal adrenal cortex. Endocr Rev (1997) 18:378-403. doi:10.1210/edrv.18.3.0304
16. Anderson DJ. Molecular control of cell fate in the neural crest: the sympathoadrenal lineage. Annu Rev Neurosci (1993) 16:129-58. doi:10.1146/annurev.neuro.16.1.129
17. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, et al. WT-1 is required for early kidney development. Cell (1993) 74:679-91. doi:10.1016/0092-8674(93)90515-R
18. Majdic G, Young M, Gomez-Sanchez E, Anderson P, Szczepaniak LS, Dobbins RL, et al. Knockout mice lacking steroidogenic factor 1 are a novel genetic model of hypothalamic obesity. Endocrinology (2002) 143:607-14. doi:10.1210/endo.143.2.8652
19. Hanley NA, Rainey WE, Wilson DI, Ball SG, Parker KL. Expression profiles of SF-1, DAX1, and CYP17 in the human fetal adrenal gland: potential interactions in gene regulation. Mol Endocrinol (2001) 15:57-68. doi:10.1210/mend.15.1.0585
20. Yu RN, Ito M, Saunders TL, Camper SA, Jameson JL. Role of Ahch in gonadal development and gametogenesis. Nat Genet (1998) 20:353-7. doi:10.1038/3822
21. Babu PS, Bavers DL, Beuschlein F, Shah S, Jeffs B, Jameson JL, et al. Interaction between Dax-1 and steroidogenic factor-1 in vivo: increased adrenal responsiveness to ACTH in the absence of Dax-1. Endocrinology (2002) 143:665-73. doi:10.1210/endo.143.2.8658
22. Bassett MH, White PC, Rainey WE. A role for the NGFI-B family in adrenal zonation and adrenocortical disease. Endocr Res (2004) 30:567-74. doi:10.1081/ERC-200043715
23. Spat A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev (2004) 84:489-539. doi:10.1152/physrev.00030.2003
24. Bandulik S, Penton D, Barhanin J, Warth R. TASK1 and TASK3 potassium channels: determinants of aldosterone secretion and adrenocortical zonation. Horm Metab Res (2010) 42:450-7. doi:10.1055/s-0029-1243601
25. Heitzmann D, Derand R, Jungbauer S, Bandulik S, Sterner C, Schweda F, et al. Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis. EMBO J (2008) 27:179-87. doi:10.1038/sj.emboj.7601934
26. Davies LA, Hu C, Guagliardo NA, Sen N, Chen X, Talley EM, et al. TASK channel deletion in mice causes primary hyperaldosteronism. Proc Natl Acad Sci U S A (2008) 105:2203-8. doi:10.1073/pnas.0712000105
27. Czirjak G, Fischer T, Spat A, Lesage F, Enyedi P. TASK (TWIK-related acid-sensitive K+ channel) is expressed in glomerulosa cells of rat adrenal cortex and inhibited by angiotensin II. Mol Endocrinol (2000) 14:863-74. doi:10.1210/mend.14.6.0466
28. Gill GN. ACTH regulation of the adrenal cortex. Pharmacol Ther B (1976) 2:313-38.
29. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev (2004) 25:947-70. doi:10.1210/er.2003-0030
30. Kraemer FB. Adrenal cholesterol utilization. Mol Cell Endocrinol (2007) 26(5-266):42-5. doi:10.1016/j.mce.2006.12.001
31. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science (1986) 232:34-47. doi:10.1126/science.3513311
32. Connelly MA, Williams DL. SR-BI and cholesterol uptake into steroidogenic cells. Trends Endocrinol Metab (2003) 14:467-72. doi:10.1016/j.tem.2003.10.002
33. Kraemer FB, Shen WJ. Hormone-sensitive lipase: control of intracellular tri-(di-)acylglycerol and cholesteryl ester hydrolysis. J Lipid Res (2002) 43:1585-94. doi:10.1194/jlr.R200009-JLR200
34. Kraemer FB, Shen WJ, Harada K, Patel S, Osuga J, Ishibashi S, et al. Hormone-sensitive lipase is required for high-density lipoprotein cholesteryl ester-supported adrenal steroidogenesis. Mol Endocrinol (2004) 18:549-57. doi:10.1210/me.2003-0179
35. Kraemer FB, Shen WJ, Natu V, Patel S, Osuga J, Ishibashi S, et al. Adrenal neutral cholesteryl ester hydrolase: identification, subcellular distribution, and sex differences. Endocrinology (2002) 143:801-6. doi:10.1210/endo.143.3.8693
36. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet (1997) 32:403-25. doi:10.2165/00003088-199732050-00005
37. Verschoor-Klootwyk AH, Verschoor L, Azhar S, Reaven GM. Role of exogenous cholesterol in regulation of adrenal steroidogenesis in the rat. J Biol Chem (1982) 257:7666-71.
38. Rone MB, Fan J, Papadopoulos V. Cholesterol transport in steroid biosynthesis: role of protein-protein interactions and implications in disease states. Biochim Biophys Acta (2009) 1791:646-58. doi:10.1016/j.bbalip.2009.03.001
39. Brock BJ, Waterman MR. Biochemical differences between rat and human cytochrome P450c17 support the different steroidogenic needs of these two species. Biochemistry (1999) 38:1598-606. doi:10.1021/bi9821059
40. Koo HJ, Lee BM. Estimated exposure to phthalates in cosmetics and risk assessment. J Toxicol Environ Health A (2004) 67:1901-14. doi:10.1080/15287390490513300
41. McKee RH, Butala JH, David RM, Gans G. NTP center for the evaluation of risks to human reproduction reports on phthalates: addressing the data gaps. Reprod Toxicol (2004) 18:1-22. doi:10.1016/j.reprotox.2003.09.002
42. Doull J, Cattley R, Elcombe C, Lake BG, Swenberg J, Wilkinson C, et al. A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines. Regul Toxicol Pharmacol (1999) 29:327-57. doi:10.1006/rtph.1999.1296
43. Koch HM, Drexler H, Angerer J. An estimation of the daily intake of di(2-ethylhexyl)phthalate (DEHP) and other phthalates in the general population. Int J Hyg Environ Health (2003) 206:77-83. doi:10.1078/1438-4639-00205
44. Frederiksen H, Aksglaede L, Sorensen K, Skakkebaek NE, Juul A, Andersson AM. Urinary excretion of phthalate metabolites in 129 healthy Danish children and adolescents: estimation of daily phthalate intake. Environ Res (2011) 111:656-63. doi:10.1016/j.envres.2011.03.005
45. Serrano SE, Braun J, Trasande L, Dills R, Sathyanarayana S. Phthalates and diet: a review of the food monitoring and epidemiology data. Environ Health (2014) 13:43. doi:10.1186/1476-069X-13-43
46. Rudel RA, Camann DE, Spengler JD, Korn LR, Brody JG. Phthalates, alkylphenols, pesticides, polybrominated diphenyl ethers, and other endocrine-disrupting compounds in indoor air and dust. Environ Sci Technol (2003) 37:4543-53. doi:10.1021/es0264596
47. Simmchen J, Ventura R, Segura J. Progress in the removal of di-[2-ethylhexyl]-phthalate as plasticizer in blood bags. Transfus Med Rev (2012) 26:27-37. doi:10.1016/j.tmrv.2011.06.001
48. Koch HM, Bolt HM, Preuss R, Eckstein R, Weisbach V, Angerer J. Intravenous exposure to di(2-ethylhexyl)phthalate (DEHP): metabolites of DEHP in urine after a voluntary platelet donation. Arch Toxicol (2005) 79:689-93. doi:10.1007/s00204-005-0004-x
49. Loff S, Hannmann T, Subotic U, Reinecke FM, Wischmann H, Brade J. Extraction of diethylhexylphthalate by home total parenteral nutrition from polyvinyl chloride infusion lines commonly used in the home. J Pediatr Gastroenterol Nutr (2008) 47:81-6. doi:10.1097/MPG.0b013e318164d933
50. FDA. Safety Assessment of Di(2-ethylhexyl)Phthalate (DEHP) Released from PVC Medical Devices. Rockville, MD: Center for Devices and Radiological Health US Food and Drug Administration (2001).
51. Kelley KE, Hernandez-Diaz S, Chaplin EL, Hauser R, Mitchell AA. Identification of phthalates in medications and dietary supplement formulations in the United States and Canada. Environ Health Perspect (2012) 120:379-84. doi:10.1289/ehp.1103998
52. Hauser R, Duty S, Godfrey-Bailey L, Calafat AM. Medications as a source of human exposure to phthalates. Environ Health Perspect (2004) 112:751-3. doi:10.1289/ehp.6804
53. Hernandez-Diaz S, Mitchell AA, Kelley KE, Calafat AM, Hauser R. Medications as a potential source of exposure to phthalates in the U.S. population. Environ Health Perspect (2009) 117:185-9. doi:10.1289/ehp.11766
54. Frederiksen H, Skakkebaek NE, Andersson AM. Metabolism of phthalates in humans. Mol Nutr Food Res (2007) 51:899-911. doi:10.1002/mnfr.200600243
55. Koch HM, Bolt HM, Preuss R, Angerer J. New metabolites of di(2-ethylhexyl)phthalate (DEHP) in human urine and serum after single oral doses of deuterium-labelled DEHP. Arch Toxicol (2005) 79:367-76. doi:10.1007/s00204-004-0642-4
56. Koch HM, Bolt HM, Angerer J. Di(2-ethylhexyl)phthalate (DEHP) metabolites in human urine and serum after a single oral dose of deuterium-labelled DEHP. Arch Toxicol (2004) 78:123-30. doi:10.1007/s00204-003-0522-3
57. Koo HJ, Lee BM. Human monitoring of phthalates and risk assessment. J Toxicol Environ Health A (2005) 68:1379-92. doi:10.1080/15287390590956506
58. Koo HJ, Lee BM. Toxicokinetic relationship between di(2-ethylhexyl) phthalate (DEHP) and mono(2-ethylhexyl) phthalate in rats. J Toxicol Environ Health A (2007) 70:383-7. doi:10.1080/15287390600882150
59. Silva MJ, Reidy JA, Herbert AR, Preau JL Jr, Needham LL, Calafat AM. Detection of phthalate metabolites in human amniotic fluid. Bull Environ Contam Toxicol (2004) 72:1226-31. doi:10.1007/s00128-004-0374-4
60. Latini G, De Felice C, Presta G, Del Vecchio A, Paris I, Ruggieri F, et al. In utero exposure to di-(2-ethylhexyl)phthalate and duration of human pregnancy. Environ Health Perspect (2003) 111:1783-5. doi:10.1289/ehp.6202
61. Sathyanarayana S, Karr CJ, Lozano P, Brown E, Calafat AM, Liu F, et al. Baby care products: possible sources of infant phthalate exposure. Pediatrics (2008) 121:e260-8. doi:10.1542/peds.2006-3766
62. Mortensen GK, Main KM, Andersson AM, Leffers H, Skakkebaek NE. Determination of phthalate monoesters in human milk, consumer milk, and infant formula by tandem mass spectrometry (LC-MS-MS). Anal Bioanal Chem (2005) 382:1084-92. doi:10.1007/s00216-005-3218-0
63. Weuve J, Sanchez BN, Calafat AM, Schettler T, Green RA, Hu H, et al. Exposure to phthalates in neonatal intensive care unit infants: urinary concentrations of monoesters and oxidative metabolites. Environ Health Perspect (2006) 114:1424-31. doi:10.1289/ehp.8926
64. Green R, Hauser R, Calafat AM, Weuve J, Schettler T, Ringer S, et al. Use of di(2-ethylhexyl) phthalate-containing medical products and urinary levels of mono(2-ethylhexyl) phthalate in neonatal intensive care unit infants. Environ Health Perspect (2005) 113:1222-5. doi:10.1289/ehp.7932
65. Fischer CJ, Bickle Graz M, Muehlethaler V, Palmero D, Tolsa JF. Phthalates in the NICU: is it safe? J Paediatr Child Health (2013) 49:E413-9. doi:10.1111/jpc.12244
66. Martinez-Arguelles DB, Campioli E, Culty M, Zirkin BR, Papadopoulos V. Fetal origin of endocrine dysfunction in the adult: the phthalate model. J Steroid Biochem Mol Biol (2013) 137:5-17. doi:10.1016/j.jsbmb.2013.01.007
67. Davis BJ, Maronpot RR, Heindel JJ. Di-(2-ethylhexyl) phthalate suppresses estradiol and ovulation in cycling rats. Toxicol Appl Pharmacol (1994) 128:216-23. doi:10.1006/taap.1994.1200
68. Lake BG, Gray TJ, Foster JR, Stubberfield CR, Gangolli SD. Comparative studies on di-(2-ethylhexyl) phthalate-induced hepatic peroxisome proliferation in the rat and hamster. Toxicol Appl Pharmacol (1984) 72:46-60. doi:10.1016/0041-008X(84)90248-5
69. Howdeshell KL, Furr J, Lambright CR, Rider CV, Wilson VS, Gray LE Jr. Cumulative effects of dibutyl phthalate and diethylhexyl phthalate on male rat reproductive tract development: altered fetal steroid hormones and genes. Toxicol Sci (2007) 99:190-202. doi:10.1093/toxsci/kfm069
70. Howdeshell KL, Wilson VS, Furr J, Lambright CR, Rider CV, Blystone CR, et al. A mixture of five phthalate esters inhibits fetal testicular testosterone production in the sprague-dawley rat in a cumulative, dose-additive manner. Toxicol Sci (2008) 105:153-65. doi:10.1093/toxsci/kfn077
71. Culty M, Thuillier R, Li W, Wang Y, Martinez-Arguelles DB, Benjamin CG, et al. In utero exposure to di-(2-ethylhexyl) phthalate exerts both short-term and long-lasting suppressive effects on testosterone production in the rat. Biol Reprod (2008) 78:1018-28. doi:10.1095/biolreprod.107.065649
72. Martinez-Arguelles DB, Culty M, Zirkin BR, Papadopoulos V. In utero exposure to di-(2-ethylhexyl) phthalate decreases mineralocorticoid receptor expression in the adult testis. Endocrinology (2009) 150:5575-85. doi:10.1210/en.2009-0847
73. Ge RS, Dong Q, Sottas CM, Latif SA, Morris DJ, Hardy MP. Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated. Mol Cell Endocrinol (2005) 243:35-42. doi:10.1016/j.mce.2005.08.004
74. Martinez-Arguelles DB, Guichard T, Culty M, Zirkin BR, Papadopoulos V. In utero exposure to the antiandrogen di-(2-ethylhexyl) phthalate decreases adrenal aldosterone production in the adult rat. Biol Reprod (2011) 85:51-61. doi:10.1095/biolreprod.110.089920
75. Martinez-Arguelles DB, McIntosh M, Rohlicek CV, Culty M, Zirkin BR, Papadopoulos V. Maternal in utero exposure to the endocrine disruptor di-(2-ethylhexyl) phthalate affects the blood pressure of adult male offspring. Toxicol Appl Pharmacol (2013) 266:95-100. doi:10.1016/j.taap.2012.10.027
76. Posnack NG, Lee NH, Brown R, Sarvazyan N. Gene expression profiling of DEHP-treated cardiomyocytes reveals potential causes of phthalate arrhythmogenicity. Toxicology (2011) 279:54-64. doi:10.1016/j.tox.2010.09.007
77. Posnack NG, Swift LM, Kay MW, Lee NH, Sarvazyan N. Phthalate exposure changes the metabolic profile of cardiac muscle cells. Environ Health Perspect (2012) 120(9):1243-51. doi:10.1289/ehp.1205056
78. Campioli E, Martinez-Arguelles DB, Papadopoulos V. In utero exposure to the endocrine disruptor di-(2-ethylhexyl) phthalate promotes local adipose and systemic inflammation in adult male offspring. Nutr Diabetes (2014) 4:e115. doi:10.1038/nutd.2014.13
79. Jepsen KF, Abildtrup A, Larsen ST. Monophthalates promote IL-6 and IL-8 production in the human epithelial cell line A549. Toxicol In vitro (2004) 18:265-9. doi:10.1016/j.tiv.2003.09.008
80. Gourlay T, Samartzis I, Stefanou D, Taylor K. Inflammatory response of rat and human neutrophils exposed to di-(2-ethyl-hexyl)-phthalate-plasticized polyvinyl chloride. Artif Organs (2003) 27:256-60. doi:10.1046/j.1525-1594.2003.07107.x
81. Ferguson KK, Loch-Caruso R, Meeker JD. Urinary phthalate metabolites in relation to biomarkers of inflammation and oxidative stress: NHANES 1999-2006. Environ Res (2011) 111:718-26. doi:10.1016/j.envres.2011.02.002
82. Trasande L, Sathyanarayana S, Spanier AJ, Trachtman H, Attina TM, Urbina EM. Urinary phthalates are associated with higher blood pressure in childhood. J Pediatr (2013) 163:747-753 e741. doi:10.1016/j.jpeds.2013.03.072
83. Martinez-Arguelles DB, Campioli E, Lienhart C, Fan J, Culty M, Zirkin BR, et al. In utero exposure to the endocrine disruptor di-(2-ethylhexyl) phthalate induces long-term changes in gene expression in the adult male adrenal gland. Endocrinology (2014) 155:1667-78. doi:10.1210/en.2013-1921
84. Romero DG, Plonczynski MW, Welsh BL, Gomez-Sanchez CE, Zhou MY, Gomez-Sanchez EP. Gene expression profile in rat adrenal zona glomerulosa cells stimulated with aldosterone secretagogues. Physiol Genomics (2007) 32:117-27. doi:10.1152/physiolgenomics.00145.2007
85. Lenzini L, Caroccia B, Campos AG, Fassina A, Belloni AS, Seccia TM, et al. Lower expression of the TWIK-related acid-sensitive K+ channel 2 (TASK-2) gene is a hallmark of aldosterone-producing adenoma causing human primary aldosteronism. J Clin Endocrinol Metab (2014) 99:E674-82. doi:10.1210/jc.2013-2900
86. Ascoli M. Characterization of several clonal lines of cultured Leydig tumor cells: gonadotropin receptors and steroidogenic responses. Endocrinology (1981) 108:88-95. doi:10.1210/endo-108-1-88
87. Dees JH, Gazouli M, Papadopoulos V. Effect of mono-ethylhexyl phthalate on MA-10 Leydig tumor cells. Reprod Toxicol (2001) 15:171-87. doi:10.1016/S0890-6238(01)00110-1
88. Svechnikova I, Svechnikov K, Soder O. The influence of di-(2-ethylhexyl) phthalate on steroidogenesis by the ovarian granulosa cells of immature female rats. J Endocrinol (2007) 194:603-9. doi:10.1677/JOE-07-0238
89. Li H, Brochu M, Wang SP, Rochdi L, Cote M, Mitchell G, et al. Hormone-sensitive lipase deficiency in mice causes lipid storage in the adrenal cortex and impaired corticosterone response to corticotropin stimulation. Endocrinology (2002) 143:3333-40. doi:10.1210/en.2002-220341
90. Osuga J, Ishibashi S, Oka T, Yagyu H, Tozawa R, Fujimoto A, et al. Targeted disruption of hormone-sensitive lipase results in male sterility and adipocyte hypertrophy, but not in obesity. Proc Natl Acad Sci U S A (2000) 97:787-92. doi:10.1073/pnas.97.2.787
91. Muczynski V, Lecureuil C, Messiaen S, Guerquin MJ, N'Tumba-Byn T, Moison D, et al. Cellular and molecular effect of MEHP Involving LXRalpha in human fetal testis and ovary. PLoS One (2012) 7:e48266. doi:10.1371/journal.pone.0048266
92. Plummer SM, Dan D, Quinney J, Hallmark N, Phillips RD, Millar M, et al. Identification of transcription factors and coactivators affected by dibutylphthalate interactions in fetal rat testes. Toxicol Sci (2013) 132:443-57. doi:10.1093/toxsci/kft016
93. Plummer S, Sharpe RM, Hallmark N, Mahood IK, Elcombe C. Time-dependent and compartment-specific effects of in utero exposure to Di(n-butyl) phthalate on gene/protein expression in the fetal rat testis as revealed by transcription profiling and laser capture microdissection. Toxicol Sci (2007) 97:520-32. doi:10.1093/toxsci/kfm062
94. Uruno A, Matsuda K, Noguchi N, Yoshikawa T, Kudo M, Satoh F, et al. Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production. J Mol Endocrinol (2011) 46:37-49. doi:10.1677/JME-10-0088
95. Pan ZQ, Xie D, Choudhary V, Seremwe M, Tsai YY, Olala L, et al. The effect of pioglitazone on aldosterone and cortisol production in HAC15 human adrenocortical carcinoma cells. Mol Cell Endocrinol (2014) 394:119-28. doi:10.1016/j.mce.2014.07.007
96. Kashiwagi Y, Mizuno Y, Harada E, Shono M, Morita S, Yoshimura M, et al. Suppression of primary aldosteronism and resistant hypertension by the peroxisome proliferator-activated receptor gamma agonist pioglitazone. Am J Med Sci (2013) 345:497-500. doi:10.1097/MAJ.0b013e31827ad893
97. Shi Y, Hon M, Evans RM. The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci U S A (2002) 99:2613-8. doi:10.1073/pnas.052707099
98. Jimenez P, Saner K, Mayhew B, Rainey WE. GATA-6 is expressed in the human adrenal and regulates transcription of genes required for adrenal androgen biosynthesis. Endocrinology (2003) 144:4285-8. doi:10.1210/en.2003-0472
99. Deng T, Shan S, Li PP, Shen ZF, Lu XP, Cheng J, et al. Peroxisome proliferator-activated receptor-gamma transcriptionally up-regulates hormone-sensitive lipase via the involvement of specificity protein-1. Endocrinology (2006) 147:875-84. doi:10.1210/en.2005-0623
100. Gazouli M, Yao ZX, Boujrad N, Corton JC, Culty M, Papadopoulos V. Effect of peroxisome proliferators on Leydig cell peripheral-type benzodiazepine receptor gene expression, hormone-stimulated cholesterol transport, and steroidogenesis: role of the peroxisome proliferator-activator receptor alpha. Endocrinology (2002) 143:2571-83. doi:10.1210/endo.143.7.8895
101. Piche CD, Sauvageau D, Vanlian M, Erythropel HC, Robaire B, Leask RL. Effects of di-(2-ethylhexyl) phthalate and four of its metabolites on steroidogenesis in MA-10 cells. Ecotoxicol Environ Saf (2012) 79:108-15. doi:10.1016/j.ecoenv.2011.12.008
102. Fan J, Traore K, Li W, Amri H, Huang H, Wu C, et al. Molecular mechanisms mediating the effect of mono-(2-ethylhexyl) phthalate on hormone-stimulated steroidogenesis in MA-10 mouse tumor Leydig cells. Endocrinology (2010) 151:3348-62. doi:10.1210/en.2010-0010
103. Champagne FA. Early environments, glucocorticoid receptors, and behavioral epigenetics. Behav Neurosci (2013) 127:628-36. doi:10.1037/a0034186
104. Entringer S, Kumsta R, Hellhammer DH, Wadhwa PD, Wust S. Prenatal exposure to maternal psychosocial stress and HPA axis regulation in young adults. Horm Behav (2009) 55:292-8. doi:10.1016/j.yhbeh.2008.11.006
105. Kaur P, Shorey LE, Ho E, Dashwood RH, Williams DE. The epigenome as a potential mediator of cancer and disease prevention in prenatal development. Nutr Rev (2013) 71:441-57. doi:10.1111/nure.12030
106. Turgeon PJ, Sukumar AN, Marsden PA. Epigenetics of cardiovascular disease-a new "beat" in coronary artery disease. Med Epigenet (2014) 2:37-52. doi:10.1159/000360766
107. Zhang X, Ho SM. Epigenetics meets endocrinology. J Mol Endocrinol (2011) 46:R11-32. doi:10.1677/JME-10-0053
108. Martinez-Arguelles DB, Papadopoulos V. Epigenetic regulation of the expression of genes involved in steroid hormone biosynthesis and action. Steroids (2010) 75:467-76. doi:10.1016/j.steroids.2010.02.004
109. Gu H, Smith ZD, Bock C, Boyle P, Gnirke A, Meissner A. Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. Nat Protoc (2011) 6:468-81. doi:10.1038/nprot.2010.190
110. Martinez-Arguelles DB, Papadopoulos V. Identification of hot spots of DNA methylation in the adult male adrenal in response to in utero exposure to the ubiquitous endocrine disruptor plasticizer di-(2-ethylhexyl) phthalate. Endocrinology (2015) 1:124-33. doi:10.1210/en.2014-1436
111. Ferguson KK, Loch-Caruso R, Meeker JD. Exploration of oxidative stress and inflammatory markers in relation to urinary phthalate metabolites: NHANES 1999-2006. Environ Sci Technol (2012) 46:477-85. doi:10.1021/es202340b
112. Bornehag CG, Nanberg E. Phthalate exposure and asthma in children. Int J Androl (2010) 33:333-45. doi:10.1111/j.1365-2605.2009.01023.x
113. Jung EM, An BS, Yang H, Choi KC, Jeung EB. Biomarker genes for detecting estrogenic activity of endocrine disruptors via estrogen receptors. Int J Environ Res Public Health (2012) 9:698-711. doi:10.3390/ijerph9030698
114. Ferguson KK, McElrath TF, Chen YH, Mukherjee B, Meeker JD. Urinary phthalate metabolites and biomarkers of oxidative stress in pregnant women: a repeated measures analysis. Environ Health Perspect (2014). doi:10.1289/ehp.1307996
115. Testai E, Galli CL, Dekant W, Marinovich M, Piersma AH, Sharpe RM. A plea for risk assessment of endocrine disrupting chemicals. Toxicology (2013) 314:51-9. doi:10.1016/j.tox.2013.07.018
116. Habert R, Livera G, Rouiller-Fabre V. Man is not a big rat: concerns with traditional human risk assessment of phthalates based on their anti-androgenic effects observed in the rat foetus. Basic Clin Androl (2014) 24:14. doi:10.1186/2051-4190-24-14
117. Habert R, Muczynski V, Grisin T, Moison D, Messiaen S, Frydman R, et al. Concerns about the widespread use of rodent models for human risk assessments of endocrine disruptors. Reproduction (2014) 147:R119-29. doi:10.1530/REP-13-0497
118. Newbold RR, Padilla-Banks E, Snyder RJ, Phillips TM, Jefferson WN. Developmental exposure to endocrine disruptors and the obesity epidemic. Reprod Toxicol (2007) 23:290-6. doi:10.1016/j.reprotox.2006.12.010
119. Desvergne B, Feige JN, Casals-Casas C. PPAR-mediated activity of phthalates: a link to the obesity epidemic? Mol Cell Endocrinol (2009) 304:43-8. doi:10.1016/j.mce.2009.02.017
120. Holm C. Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Biochem Soc Trans (2003) 31:1120-4. doi:10.1042/BST0311120
121. Qi L, Shen H, Larson I, Barnard JR, Schaefer EJ, Ordovas JM. Genetic variation at the hormone sensitive lipase: gender-specific association with plasma lipid and glucose concentrations. Clin Genet (2004) 65:93-100. doi:10.1111/j.0009-9163.2004.00196.x